文献速递神经肿瘤

挽救性经鼻蝶手术对立体定向放射外科治疗后进展的垂体腺瘤安全有效

Safe and efficacious therapeutic outcomes with salvage endonasal transsphenoidal surgery for pituitary adenoma progression following stereotactic radiosurgery.
PubMed 文献 · J Neurosurg · 2025-02-28

这项回顾性两机构队列研究分析13例因垂体腺瘤在立体定向放射外科(SRS)治疗后进展而接受挽救性经鼻蝶手术(sETS)的患者,并与倾向评分匹配后的原发经鼻蝶手术(pETS)组比较。sETS后无新发神经功能缺损或死亡,中位肿瘤切除率90%,5年无进展生存率和疾病特异生存率分别为55%和77%。匹配队列中sETS组与pETS组手术结局无显著差异。

要点

  • sETS后无患者出现新发神经功能缺损或死亡,中位肿瘤切除率90%。
  • sETS后5年无进展生存率55%,疾病特异生存率77%。
  • sETS后复发的4例(31%)均为促肾上腺皮质激素型肿瘤。

核心结论

  • 作者结果表明,经鼻蝶手术可作为SRS失败后的挽救治疗安全实施,并发症率低,对治疗抵抗的垂体腺瘤肿瘤控制满意。

研究设计与样本

  • 回顾性两机构队列研究,分析因垂体腺瘤在SRS后进展而接受sETS的患者,并与pETS组按手术时年龄、最大肿瘤直径、最高Knosp-Steiner分级和肿瘤类型进行倾向评分匹配后比较。
  • sETS组共13例(男性8例[62%]),手术时中位年龄56岁,肿瘤类型为非功能型5例(39%)、促肾上腺皮质激素型6例(46%)、其他功能型2例(15%),中位随访125个月(范围23-169个月)。
  • 匹配队列分析中sETS组12例与pETS组12例进行比较。

主要发现

  • sETS后无患者出现新发神经功能缺损或死亡,中位肿瘤切除率90%(范围80%-100%)。
  • sETS后5年无进展生存率和疾病特异生存率分别为55%和77%。
  • sETS后复发的4例患者(31%)均为促肾上腺皮质激素型肿瘤。
  • 匹配队列中sETS组与pETS组手术结局无显著差异;3年无进展生存率sETS组80% vs pETS组49%(p=0.216,log-rank检验),疾病特异生存两组相似(p=0.543,log-rank检验)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Stereotactic radiosurgery (SRS) offers excellent tumor control for pituitary adenoma (PA); however, treatment failure occasionally necessitates salvage surgery. Comprehensive studies on salvage surgical outcomes for recurrent PA after SRS remain scarce. This study aimed to elucidate the outcomes of salvage endonasal transsphenoidal surgery (sETS) for progressive PA failing SRS. METHODS: This retrospective, two institution-based cohort study analyzed data from patients who underwent sETS for progressive PA failing SRS. Progression-free survival (PFS), disease-specific survival (DSS), and neurological and endocrinological outcomes in the sETS group were analyzed and compared with those in the primary ETS (pETS) group after propensity score matching using the following variables: age at surgery, maximum tumor diameter, highest Knosp-Steiner classification, and tumor type. RESULTS: Thirteen sETS patients (8 males [62%], median age at surgery of 56 years) with 5 nonfunctioning (39%), 6 corticotropic (46%), and 2 other functioning (15%) PAs who received median (range) follow-up of 125 ( 23-169) months were included. None of the patients experienced new neurological deficits or death after sETS. The median (range) tumor resection rate was 90% (80%-100%). The 5-year PFS and DSS rates were 55% and 77%, respectively. All 4 patients (31%) who experienced recurrence after sETS had corticotropic tumors. In the matched cohort analysis between the sETS group with 12 patients and the pETS group with 12 patients, no significant differences were observed in surgical outcomes. PFS rates were marginally higher in the sETS group than in the pETS group (80% vs 49% at 3 years, p = 0.216, log-rank test), and DSS was similar between the two groups (p = 0.543, log-rank test). CONCLUSIONS: The authors' results indicate that ETS can be safely performed as a salvage treatment after failed SRS with low complication rates and satisfactory tumor control in treatment-resistant PA.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Shinya Y, Hong S, Wipplinger C, et al. Safe and efficacious therapeutic outcomes with salvage endonasal transsphenoidal surgery for pituitary adenoma progression following stereotactic radiosurgery. J Neurosurg. 2025. PMID: 40020238. doi:10.3171/2024.10.JNS241682

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。